Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA reports news on its commercial-stage oncology business focused on antibody-drug conjugates. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC with FDA accelerated approval and European Commission conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Recurring updates cover ZYNLONTA product revenue, manufacturing and commercialization activity, clinical development in combination regimens and earlier lines of therapy, including LOTIS program studies, and corporate financing matters. Company news also includes quarterly financial results, investor presentations, conference participation and equity inducement grants under its compensation plans.
ADC Therapeutics SA (NYSE: ADCT) announced the FDA's acceptance of its Biologics License Application (BLA) for loncastuximab tesirine (Lonca), targeting relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with a priority review status. A PDUFA target date is set for May 21, 2021. The BLA is based on the LOTIS 2 trial, reporting a 48.3% overall response rate among 145 patients. Common severe adverse events included neutropenia (25.5%) and thrombocytopenia (17.9%). Long-term efficacy and safety data are pending further studies.
ADC Therapeutics (ADCT) reported its third quarter 2020 financial results and business highlights. Key points include the submission of a Biologics License Application for its drug Lonca to the FDA for treating relapsed DLBCL, with a commercial launch planned for mid-2021. The company initiated Phase 3 and Phase 2 clinical trials for Lonca, showing promising preliminary data from ongoing trials. Cash and cash equivalents reached $494.4 million. However, the adjusted net loss widened to $41.3 million from $31.1 million year-over-year, mainly due to increased operational costs.
ADC Therapeutics SA (NYSE: ADCT) announced that CEO Chris Martin will present a company overview at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 9:20 am ET. A live webcast will be accessible, and an archived version will be available post-event. The company specializes in developing antibody drug conjugates (ADCs) for hematological malignancies and solid tumors, with lead products Loncastuximab tesirine and Camidanlumab tesirine showing promising results in pivotal trials. For more details, visit adctherapeutics.com.
ADC Therapeutics (NYSE: ADCT) announces a conference call on November 12, 2020, at 8:30 AM ET to discuss its financial results for Q3 2020 and provide business updates. The call can be accessed via phone or live webcast. The company focuses on developing targeted antibody drug conjugates (ADCs) for treating hematological malignancies and solid tumors. Key product candidates include Loncastuximab tesirine, which demonstrated a 48.3% overall response rate in a pivotal clinical trial, and Camidanlumab tesirine, with an 86.5% response rate in Hodgkin lymphoma patients.
ADC Therapeutics SA (NYSE:ADCT) announced eight abstracts for presentation at the 62nd ASH Annual Meeting, focusing on the efficacy of its ADCs, particularly loncastuximab tesirine (Lonca) and camidanlumab tesirine (Cami). The data includes results from pivotal trials, showcasing a 48.3% overall response rate for Lonca in relapsed/refractory diffuse large B-cell lymphoma. The abstracts will be published in the November supplemental issue of Blood. ADC Therapeutics is positioned as a leader in developing targeted therapies for hematological malignancies.
ADC Therapeutics (NYSE: ADCT) announced the dosing of the first patient in a Phase 1b clinical trial evaluating camidanlumab tesirine (Cami) in combination with pembrolizumab for advanced solid tumors. This trial aims to identify a dosing regimen and assess clinical activity. Previous data supports this combination approach, which targets CD25 on regulatory T cells. Approximately 95 patients will participate in the trial, part of ADC's ongoing commitment to develop innovative cancer therapies.
Genmab and ADC Therapeutics have amended their agreement to further develop camidanlumab tesirine (Cami), an antibody-drug conjugate targeting CD25. Originally established in 2013, the collaboration aims to enhance Cami's commercialization prospects following positive Phase 1 clinical trial results showing an 86.5% overall response rate in Hodgkin lymphoma patients. ADC Therapeutics is currently conducting a pivotal Phase 2 trial with over 50% enrollment, anticipating interim results in H1 2021. Under the new terms, Genmab will receive a tiered royalty on net sales instead of a divestment opportunity.
ADC Therapeutics SA (NYSE: ADCT) announced that underwriters of its upsized public offering, which closed on September 28, 2020, fully exercised their option to purchase an additional 900,000 common shares at $34 each. The company did not receive proceeds from this sale. Morgan Stanley, BofA Securities, and Cowen served as joint book-running managers. ADC Therapeutics focuses on developing antibody drug conjugates for hematological malignancies and solid tumors, with lead candidates Loncastuximab tesirine and Camidanlumab tesirine currently in pivotal clinical trials.
ADC Therapeutics has announced the pricing of its initial public offering (IPO) of 12,245,631 shares at $19.00 per share, aiming for $232.7 million in gross proceeds. Trading is set to begin on the New York Stock Exchange under the ticker symbol ADCT on May 15, 2020, with the offering closing on May 19, 2020. The underwriters have a 30-day option to purchase an additional 1,836,844 shares. ADC Therapeutics focuses on developing targeted antibody drug conjugates for treating hematological malignancies and solid tumors.